Fig. 5From: Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical dataCumulative incidence of HCC in at-risk participants. Participants were divided into two groups based on baseline PIVKA-II levels. Cumulative incidences were calculated in all enrolled groups (a) and patients with cirrhosis (b). Dashed lines are interquartile rangesBack to article page